These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37856496)

  • 1. Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study.
    Ayinde O; Ross JDC; Jackson L
    PLoS One; 2023; 18(10):e0292273. PubMed ID: 37856496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gentamicin as an alternative to ceftriaxone in the treatment of gonorrhoea: the G-TOG non-inferiority RCT.
    Ross JD; Harding J; Duley L; Montgomery AA; Hepburn T; Tan W; Brittain C; Meakin G; Sprange K; Thandi S; Jackson L; Roberts T; Wilson J; White J; Dewsnap C; Cole M; Lawrence T
    Health Technol Assess; 2019 May; 23(20):1-104. PubMed ID: 31099330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial.
    Brittain C; Childs M; Duley L; Harding J; Hepburn T; Meakin G; Montgomery AA; Tan W; Ross JD
    Trials; 2016 Nov; 17(1):558. PubMed ID: 27881151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial resistance point-of-care testing for gonorrhoea treatment regimens: cost-effectiveness and impact on ceftriaxone use of five hypothetical strategies compared with standard care in England sexual health clinics.
    Harding-Esch EM; Huntington SE; Harvey MJ; Weston G; Broad CE; Adams EJ; Sadiq ST
    Euro Surveill; 2020 Oct; 25(43):. PubMed ID: 33124553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic reviews and mathematical modelling.
    Althaus CL; Turner KM; Mercer CH; Auguste P; Roberts TE; Bell G; Herzog SA; Cassell JA; Edmunds WJ; White PJ; Ward H; Low N
    Health Technol Assess; 2014 Jan; 18(2):1-100, vii-viii. PubMed ID: 24411488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of
    Turner KM; Christensen H; Adams EJ; McAdams D; Fifer H; McDonnell A; Woodford N
    BMJ Open; 2017 Jun; 7(6):e015447. PubMed ID: 28615273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.
    Ross JDC; Brittain C; Cole M; Dewsnap C; Harding J; Hepburn T; Jackson L; Keogh M; Lawrence T; Montgomery AA; Roberts TE; Sprange K; Tan W; Thandi S; White J; Wilson J; Duley L;
    Lancet; 2019 Jun; 393(10190):2511-2520. PubMed ID: 31056291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the costs and outcomes of control programmes for sexually transmitted infections: a systematic review of economic evaluations.
    Bloch SCM; Jackson LJ; Frew E; Ross JDC
    Sex Transm Infect; 2021 Aug; 97(5):334-344. PubMed ID: 33653881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics for treating gonorrhoea in pregnancy.
    Comunián-Carrasco G; Peña-Martí GE; Martí-Carvajal AJ
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011167. PubMed ID: 29465747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based interventions for reducing sexually transmitted infections, including HIV infection.
    Sangani P; Rutherford G; Wilkinson D
    Cochrane Database Syst Rev; 2004; (2):CD001220. PubMed ID: 15106156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
    de Vries HJC; de Laat M; Jongen VW; Heijman T; Wind CM; Boyd A; de Korne-Elenbaas J; van Dam AP; Schim van der Loeff MF;
    Lancet Infect Dis; 2022 May; 22(5):706-717. PubMed ID: 35065063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.
    Unemo M
    BMC Infect Dis; 2015 Aug; 15():364. PubMed ID: 26293005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based interventions for reducing sexually transmitted infections, including HIV infection.
    Wilkinson D; Rutherford G
    Cochrane Database Syst Rev; 2001; (2):CD001220. PubMed ID: 11405980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.
    Schnitzler L; Evers SMAA; Jackson LJ; Paulus ATG; Roberts TE
    BMC Public Health; 2022 Nov; 22(1):2180. PubMed ID: 36434561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete ciprofloxacin resistance in gonococcal isolates in an urban Ugandan clinic: findings from a cross-sectional study.
    Mabonga E; Parkes-Ratanshi R; Riedel S; Nabweyambo S; Mbabazi O; Taylor C; Gaydos C; Manabe YC
    Int J STD AIDS; 2019 Mar; 30(3):256-263. PubMed ID: 30392463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study.
    Reichert E; Yaesoubi R; Rönn MM; Gift TL; Salomon JA; Grad YH
    Lancet Microbe; 2023 Oct; 4(10):e781-e789. PubMed ID: 37619582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in antimicrobial management of gonorrhoea by general practitioners in Amsterdam, the Netherlands, between 2010 and 2016: a cross-sectional study.
    van Amerongen R; Gazendam RP; van Bergen JEAM
    BMC Fam Pract; 2019 Jan; 20(1):12. PubMed ID: 30646849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial resistance in Neisseria gonorrhoeae isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009-2019.
    Aniskevich A; Shimanskaya I; Boiko I; Golubovskaya T; Golparian D; Stanislavova I; Jacobsson S; Adaskevich A; Unemo M
    BMC Infect Dis; 2021 Jun; 21(1):520. PubMed ID: 34078300
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.